Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
NCT00083434 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2011-04-27
Summary
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Conditions
Interventions
- DRUG
-
Epoetin alfa
Sponsors & Collaborators
-
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-02-29
- Completion
- 2004-10-31
Countries
- United States
Study Locations
More Related Trials
-
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
NCT00270166 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
NCT00266617 ·Status: COMPLETED ·Phase: PHASE2
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
NCT00003341 ·Status: COMPLETED ·Phase: PHASE3
-
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
NCT00481624 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
NCT00269997 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
NCT01394991 ·Status: COMPLETED ·Phase: PHASE4
-
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
NCT00416624 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
NCT00216541 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
NCT00350090 ·Status: TERMINATED ·Phase: PHASE3
-
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
NCT00310232 ·Status: TERMINATED ·Phase: PHASE3
-
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
NCT00148421 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
NCT00341055 ·Status: COMPLETED ·Phase: PHASE3
-
Anemia in Patients With a Non-Myeloid Malignancy
NCT00038064 ·Status: COMPLETED ·Phase: PHASE3
-
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
NCT00875004 ·Status: TERMINATED ·Phase: NA
-
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
NCT00210587 ·Status: COMPLETED ·Phase: PHASE3
-
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00070382 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
NCT00386152 ·Status: TERMINATED ·Phase: PHASE2
-
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
NCT00388336 ·Status: COMPLETED ·Phase: PHASE2
-
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
NCT00858364 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
NCT00120679 ·Status: COMPLETED ·Phase: PHASE2
-
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00022386 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
NCT00210834 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
NCT00628043 ·Status: COMPLETED ·Phase: PHASE3
-
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
NCT00661999 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
NCT00211133 ·Status: COMPLETED ·Phase: PHASE3